{"id":"W4407392510","doi":"10.1158/1078-0432.ccr-24-1818","title":"AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Durvalumab; Medicine; Tolerability; Combination therapy; Adverse effect; Internal medicine; Toxicity; Pharmacology; Cancer; Urology; Oncology; Gastroenterology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000698053,0.0008052898,0.001088793,0.0002938826,0.0002262652,0.0004878381,0.0005001213,0.0005404601,0.001236439],"category_scores_gemma":[0.0003953275,0.000257389,0.0005276566,0.0002880465,0.0005217696,0.0004235382,0.000190497,0.001472668,0.0003230149],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006664247,"about_ca_system_score_gemma":0.0007386312,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007842145,"about_ca_topic_score_gemma":0.002015132,"domain_scores_codex":[0.9998134,0.00007693819,0.00001292961,0.00002772941,0.00002781891,0.00004135928],"domain_scores_gemma":[0.9997438,0.0000552674,0.00004513745,0.0000161348,0.00001597193,0.0001236635],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4214061,0.04917463,0.01731477,0.001490053,0.00222712,0.0007092385,0.0005859346,0.005842342,0.1369127,0.0006807761,0.005995291,0.3576609],"study_design_scores_gemma":[0.486207,0.4587107,0.02419798,0.00006337966,0.000787454,0.0008788044,0.0001013891,0.004691722,0.01931099,0.0002534665,0.004761851,0.00003521186],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995271,0.0024799,0.0003280251,0.0002467241,0.00005699662,0.0003781554,0.000271974,0.0000522451,0.0009149757],"genre_scores_gemma":[0.9948237,0.001976983,0.001000997,0.0002974774,0.00009008248,0.0003193083,0.0006368197,0.00000915754,0.0008454999],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001236439,"threshold_uncertainty_score":0.004835248,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06226559789994827,"score_gpt":0.4923652683580123,"score_spread":0.430099670458064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}